Journal Mobile Options
Table of Contents
Vol. 18, No. 3-4, 2004
Issue release date: October 2004

Subtle Memory Decline over 12 Months in Mild Cognitive Impairment

Maruff P. · Collie A. · Darby D. · Weaver-Cargin J. · Masters C. · Currie J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: Screening of normal older persons for progressive memory decline is a worthwhile strategy in the pursuit of the earliest possible stages of pre-clinical Alzheimer’s disease (AD) or mild cognitive impairment (MCI). Reliable tests are needed to both detect MCI and measure the natural history of decline over months rather than years. We aimed to detect memory decline over 1 year in a group of older individuals with well-characterised amnestic MCI. Methods: The continuous learning task (CLT) from the CogState test battery was administered 8 times in 12 months to 15 individuals with MCI and 35 controls matched for age, education, IQ and gender. All subjects were recruited from an ongoing aging study. The rate of change in CLT performance over the year was compared between groups and also compared to that detected with a word list learning task and a computerised paired associate learning task. Results: At baseline, memory performance in the amnestic MCI group was significantly worse than controls on all memory tests. However, at 12 months the magnitude of the difference between the groups had increased significantly on the CLT due to decline in memory accuracy in the MCI group. No decline over 12 months was detectable on the routine memory tests. Conclusions: Subtle memory decline is detectable in amnestic MCI using reliable and sensitive tests of memory. Such measures may assist in the early identification of AD and also in trials of putative disease-modifying therapies to be conducted over as little as 12 months.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Storandt M, Grant EA, Miller P, Morris JC: Rates of progression in mild cognitive impairment and early Alzheimer’s disease. Neurology 2002;59:1034–1141.
  2. Bennet DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggerwal NT, Barnes LL, Fox JH, Bach J: Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198–205.
  3. Collie A, Maruff P: The neuropsychology of preclinical Alzheimer’s disease and mild cognitive impairment. Neurosci Biobehav Rev 2000;24:365–374.
  4. Petersen RC, Doody R, Kurz A, Mohs R, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.
  5. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST: Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–1142.
  6. Jack CR, Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E: Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397–1403.
  7. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, Tanzi R, Jones K, Albert MS: MRI measures of entorhinal cortex vs. hippocampus in preclinical AD. Neurology 2002;58:1188–1196.
  8. Dekosky ST, Ikonomovic M, Styren SD, et al: Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 2002;51:145–155.
  9. Morris JC, Storandt M, McKeel DW, et al: Cerebral amyloid deposition and diffuse plaques in normal aging: evidence for presymptomatic and very mild Alzheimer’s disease. Neurology 1996;46:707–719.
  10. Albert MS: Preclinical predictors of Alzheimer’s disease. Brain Cognit 1999;35:756–759.
  11. Gomez-Isla T, Price JL, McKeel DW Jr, et al: Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 1996;16:4491–4500.
  12. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica (Berlin) 1991;82:239–259.
  13. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  14. Bowen J, Teri L, Kukull W, McCormick W, McCurry SM, Larson EB: Progression to dementia in patients with isolated memory loss. Lancet 1997;349:763–765.
  15. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL: Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001;58:411–416.
  16. Tierney MC, Szalai JP, Snow WG, et al: Prediction of probable Alzheimer’s disease in memory-impaired patients: A prospective longitudinal study. Neurology 1996;46:661–665.
  17. Collie A, Maruff P, Currie J: Behavioural characterisation of mild cognitive impairment. J Clin Exp Neuropsychol, in press.
  18. Collie A, Maruff P: The neuropsychology of preclinical Alzheimer’s disease and mild cognitive impairment. Neurosci Biobehav Rev 2000;24:365–374.
  19. Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PR, Masters CL, Currie J: Memory decline in healthy older people: Implications for identifying mild cognitive impairment. Neurology 2001;56:1533–1538.
  20. Collie A, Maruff P, Darby D: The effects of practice on cognitive test performance of neurologically normal individuals at brief test-retest intervals. J Int Neuropsychol Soc 2003;9:419–428.
  21. Darby D, Maruff P, Collie A, McStephen M: Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology 2002;59:1042–1046.
  22. McCaffrey RJ, Duff K, Westervelt HJ: Practitioner’s Guide to Evaluating Change with Neuropsychological Assessment Instruments. New York, Kluwer Academic/Plenum Publishers, 2000.
  23. Salthouse TA: Aging associations – Influence of speed on adult age differences in associative learning. J Exp Psychol Learn Mem Cogn 1994;20:1486–1503.
  24. Whyte S, Wilson N, Currie J, Maruff P, Malone V, Shafiq-Antonacci R, Tyler P, Derry KL, Underwood J, Li QX, Beyreuther K, Masters CL: Collection and normal levels of the amyloid precursor protein in plasma. Ann Neurol 1997;41:121–124.
  25. Collie A, Shafiq-Antonacci R, Maruff P, Tyler P, Currie J: Norms and the effects of demographic variables on a neuropsychological battery for use in healthy ageing Australian populations. Aust NZ J Psychiat 1999;33:568–575.
  26. Zakzanis KK: Statistics to tell the truth, the whole truth and nothing but the truth. Formulae, illustrative numerical examples and heuristic interpretation of effect size analysis for neuropsychological researchers. Arch Clin Neuropsychol 2001;16:653–667.
  27. Ritchie K, Artero S, Touchon J: Classification criteria for mild cognitive lmpairment: A population-based validation study. Neurology 2001;56:37–42.
  28. Morris JC: Challanging assumptions about Alzheimer’s disease: Mild cognitive impairment and the cholinergic hypothesis. Ann Neurol 2002;51:143–144.
  29. Reischies FM, Hellweg R: Prediction of deterioration in mild cognitive disorder in old age – neuropsychological and neurochemical parameters of dementia diseases. Compr Psychiatry 2000;41:66–75.
  30. O’Carroll R: The assessment of premorbid ability a critical review. Neurocase 1995;1:83–89.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50